1. a) M. Buchbinder, J. C. Webb, L. V. Anderson, W. R. McCabe. Laboratory studies and clinical pharmacology of nalidixic acid. Antimicrob. Agents Chemother, 1962, 2, 308–317 b) G. Y. Lesher, E. D. Forelich, M. D. Gruet, J. H. Bailey, R. P. Brundage. 1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents. J. Med. Pharm. Chem, 1962, 5, 1063–1068.
2. a) K. E. Brighty, T. D. Gootz. (Eds: V. T. Andriole), In the Quinolones, 3rd ed. Academic Press, 2000, Chemistry and mechanism of action of the quinolone antibacterials, 33–97 b) H. J. Senf. Fluorochinolone (Gyrasehemmer). Pharmazie, 1988, 43, 444–447 c) J. T. Smith, C. S. Lewin. (Eds: V. T. Andriole), In the Quinolones. Academic Press, 1988, Chemistry and mechanisms of action of the quinolone antibacterials, 23–81.
3. S. L. Gorbach, K. W. Nelson. (Eds: A. P. R. Wilson, R. N. Gruneberg), Ciprofloxacin: 10 Years of Clinical Experience. Maxim Medical, 1997. p. 67.
4. DNA gyrase: an enzyme that introduces superhelical turns into DNA.
5. a) S. C. Kampranis, A. Maxwell. The DNA gyrase–quinolone complex ATP hydrolysis and the mechanism of DNA cleavage. J. Biol. Chem, 1998, 273, 22615–22626 b) G. Palu, S. Valisena, G. Ciarrocchi, B. Gatto, M. Palumbo. Quinolone binding to DNA is mediated by magnesium ions. Proc. Natl. Acad. Sci. U.S.A., 1992, 89, 9671–9675.